Browsing Tag
CT:VQ
7 posts
4DMedical wins Australian CT:VQ approval as ASX:4DX faces Medicare reimbursement test
4DMedical has gained regulatory access to its home market for CT:VQ, but the commercial value of Australia’s large CT scanner network will depend on hospital implementation, clinical confidence and Medicare reimbursement.
4DMedical (ASX: 4DX) stock up 7.3% as Mayo Clinic adoption and GSK contract reset lung imaging story
Nuclear medicine VQ scans are a US$1 billion market. 4DMedical (ASX: 4DX) just landed Mayo Clinic, GSK, and Medicare. The question is now scan volume scaling speed.
4DMedical (ASX: 4DX) secures CE Mark for CT:VQ and raises A$83m to accelerate European commercial launch
4DMedical (ASX: 4DX) secures CE Mark for CT:VQ and raises A$83M to fund EU expansion. Read what this means for investors and the respiratory imaging sector.
Why 4DMedical (ASX: 4DX) stock is gaining momentum after A$22.6m option exercise and cash runway boost
4DMedical (ASX: 4DX) raises A$22.6m via option exercise, boosting its cash balance to A$45.5m. Investors eye CT:VQ rollout and RSNA 2025 milestones.
4DMedical’s CT:VQ clearance could mark the end of nuclear VQ scans—is the industry ready for software-first lung imaging?
4DMedical’s FDA-cleared CT:VQ may replace nuclear lung scans with software-powered diagnostics. Explore how this breakthrough is reshaping imaging standards.
How 4DMedical’s CT:VQ is rewriting the rules of lung imaging—no radiotracers, no waiting rooms, just pixels
CT:VQ gets FDA clearance—and 4DMedical may be the new standard in lung imaging. Discover how this Aussie SaaS medtech is reshaping respiratory diagnostics.
Why 4DMedical stock is suddenly soaring—and how FDA approval could open a billion-dollar market
4DMedical stock jumps 35% as CT:VQ earns FDA clearance. Find out how this breakthrough in lung imaging is reshaping the USD $1.1B VQ scan market.